Drugs / TIZATERKIB
TIZATERKIB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04305249 | Aug 2020 → Apr 2024 | cancer, hematopoietic and lymphoid cell neoplasm | Antengene Therapeutics Limited | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2023-04-18 | Antengene Corporation | Results Antengene Announces Five Presentations at the 2023 American Association for Cancer Research Meeting antengene.com ↗
Five posters showcased progress with multiple preclinical and clinical programs, including ATG-008 (mTORC1/2 inhibitor), ATG-017 (ERK1/2 inhibitor), ATG-037 (CD73 inhibitor), ATG-031 (anti-CD24 monoclonal antibody) and ATG-034 (LILRB4 antagonist antibody) |
| 2022-11-01 | Antengene Corporation | Regulatory Antengene Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors antengene.com ↗ |
| 2022-03-09 | Antengene Corporation | Results Antengene Announces Five Upcoming Presentations at the 2022 American Association for Cancer Research Annual Meeting antengene.com ↗
These data provide several promising combination strategies for ATG-012 that could be utilized in clinical testing for cancer patients with the KRAS G12C mutation. |
| 2021-11-15 | Antengene Corporation | Results Antengene Presents Compelling Preclinical Data on Two Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 12, 2021 antengene.com ↗
Data in the poster showed that the combination enhanced the antitumor efficacy as well as increasing the percentage of infiltrating CD8+ T cells, NK cells, CD8:CD4 ratio and M1:M2 macrophage ratio in the tumor microenvironment, rendering a “cold” tumor “hot”. |
| 2020-08-13 | Antengene Corporation | Regulatory Australian Therapeutic Goods Administration (TGA) Approves the First Phase I Trial of ATG-017 (ERK 1/2 inhibitor) for the Treatment of Patients with Advanced Solid Tumors and Hematological Malignancies antengene.com ↗
Antengene Corporation, a leading innovative hematology and oncology-focused biopharmaceutical company, announced today the authorization of the first-in-human trial of ATG-017 (ERASER trial) by the Australian Therapeutic Goods Administration (TGA). |
All press releases naming this drug 9 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TIZATERKIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4482864 ↗ |
| Known as | ATG-017 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04305249 ↗ |
| Known as | AZ-13820216 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4482864 ↗ |
| Known as | AZD-0364 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4482864 ↗ |
| Modality | Small molecule | — CHEMBL4482864 ↗ |
| Route | Oral | “ATG-017 administered orally” NCT04305249 ↗ |